Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
3. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
4. Mode of action of T cells engineered with CAR or TCR for cancer treatment
- Prof. Sebastian Kobold
-
5. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
6. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
7. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
8. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
9. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
11. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
12. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
13. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
15. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
16. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
17. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
18. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
19. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
20. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
22. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
23. Hemophilia A
- Dr. Snejana Krassova
-
26. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
27. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
28. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
29. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
30. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
31. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
32. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
33. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
34. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
35. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
36. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
37. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
38. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
39. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
40. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
42. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
43. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
44. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
45. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
46. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
47. Cow’s milk allergy: the future
- Dr. Carina Venter
-
48. Cow's milk allergy: management
- Dr. Carina Venter
-
49. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
50. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
51. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
52. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
53. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
54. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
55. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
56. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
57. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
58. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
60. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
61. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
62. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
63. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
64. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
65. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
66. Molecular brain imaging (PET) in diseases with dementia
- Prof. Karl Herholz
-
67. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
68. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
69. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
70. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
71. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
72. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
73. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
74. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
75. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
76. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
77. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
78. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
79. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
80. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
81. AI and big data in drug discovery
- Mr. Ed Addison
-
82. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
83. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
84. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
85. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
86. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
87. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
88. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
89. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
90. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
91. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
92. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
93. New drugs for asthma
- Prof. Peter Barnes
-
94. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
95. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
Printable Handouts
Navigable Slide Index
- Introduction
- DILI topics to be discussed
- Magnitude of DILI
- What is DILI?
- Clinical syndromes (phenotypes) associated with DILI: one of the great Imitators in medicine
- Drug-Induced Liver Injury
- History of DILI through the decades
- History of DILI through the decades (cont.)
- Regulatory science and DILI
- DILI is rare but often dramatic
- DILI in drug development
- Causes of acute liver failure in the US
- Causes of acute liver failure and specific drug-induced causes in the U.S. acute liver failure study group*
- Epidemiology of DILI
- Epidemiology of DILI: population-based studies
- Epidemiology of DILI: more population-based studies
- DILI in mainland China
- Causes of acute DILI in the updated US DILIN registry
- Most common individual drugs implicated in the U.S. DILIN
- Top 25 drugs causing acute DILI in the U.S. DILIN account for two-thirds of all DILI cases
- Top causes of DILI from global registries
- Causes of DILI in mainland China among 25,927 hospitalized patients
- Historical mechanisms of DILI
- Acetaminophen overdose
- Acetaminophen (paracetamol) hepatotoxicity
- Acetaminophen undetected in plasma in >50% patients believed to have acute liver failure due to overdose
- Acetaminophen overdose: the differences between men and women
- Acetaminophen: well-defined hepatotoxic mechanism
- 2 historical types of idiosyncratic DILI
- Proposed third phenotype of DILI
- Expanded mechanisms of DILI
- Linking reactive metabolites and immune response causing iDILI
- Clinical adaptation (drug tolerance)
- Bile salt export pump and DILI
- Auto-immune-like DILI
- Clinical features of drug-induced autoimmune hepatitis vs. idiopathic AIH at Mayo Clinic
- Immune-mediated hepatitis
- Thank you for listening
Topics Covered
- History of Drug-Induced Liver Injury (DILI)
- Epidemiology of DILI
- Causes of acute liver failure
- Mechanisms of DILI
- Phenotypes of DILI
- Drug-induced autoimmune hepatitis, idiopathic autoimmune hepatitis, and immune-mediated hepatitis
Links
Series:
- Gastroenterology and Hepatology
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
Talk Citation
Lewis, J.H. (2021, January 31). Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 1, 2024, from https://doi.org/10.69645/KVYQ9854.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. James H. Lewis has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
Published on January 31, 2021
46 min
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
This is Dr. James H. Lewis.
I'm a professor of medicine and the Director of Hepatology in the division of
Gastroenterology at Georgetown University Medical Center, in Washington DC.
The topic for today's discussion is drug-induced liver injury (DILI):
where we've been, and where we are headed.
0:19
In the first part of my talk
I'm going to be discussing the importance of drug-induced liver injury, its epidemiology,
and the specific causes of drug-induced liver injury,
along with the mechanisms by which drugs can injure the liver.
In the second part of the talk
we'll be discussing risk factors for drug-induced liver injury,
including many of the host -
as well as pharmacologic - risk factors, along with
the recent research into pharmaco-genomic discovery.
The third part of the talk will include the rising incidence
of herbal and dietary supplement-related hepatotoxicity, and
the current methods by which we attempt to
diagnose DILI and the strategies used to treat and prevent DILI.
1:14
The magnitude of DILI is immense.
While it's rare to be seen in the clinic,
DILI's impact on drug development and
clinical practice is out of proportion to its incidence.
More than 700 drugs, herbal agents,
and chemicals have been implicated in causing drug-induced liver injury,
and it's the leading cause of
acute liver failure in the United States and other countries,
especially when we include acetaminophen (or paracetamol) as a cause.
It's also the leading cause of the failure to grant new drug approvals,
and has been the reason for withdrawal of new drugs in development.
About 7,000 DILI citations were cited between the year 2000 and 2009,
or about 700 annually.
Since then in the past decade,
over 6,000 citations were seen up to 2014, and currently
more than 1,500 publications dealing with drug-induced liver injury and
other aspects of hepatotoxicity have appeared annually since 2014.
What is drug-induced liver injury (DILI)?
Hide